These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 35755897)
1. Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia. Waggoner M; Katsetos J; Thomas E; Galinsky I; Fox H J Adv Pract Oncol; 2022 May; 13(4):400-415. PubMed ID: 35755897 [TBL] [Abstract][Full Text] [Related]
2. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301 [TBL] [Abstract][Full Text] [Related]
3. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635 [TBL] [Abstract][Full Text] [Related]
4. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097 [TBL] [Abstract][Full Text] [Related]
5. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474 [TBL] [Abstract][Full Text] [Related]
6. Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy. Richard-Carpentier G; DiNardo CD Ther Adv Hematol; 2019; 10():2040620719882822. PubMed ID: 31692757 [TBL] [Abstract][Full Text] [Related]
7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
9. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. DiNardo CD; Pratz K; Pullarkat V; Jonas BA; Arellano M; Becker PS; Frankfurt O; Konopleva M; Wei AH; Kantarjian HM; Xu T; Hong WJ; Chyla B; Potluri J; Pollyea DA; Letai A Blood; 2019 Jan; 133(1):7-17. PubMed ID: 30361262 [TBL] [Abstract][Full Text] [Related]
10. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis. Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400 [TBL] [Abstract][Full Text] [Related]
11. Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia. Sciumè M; Bosi A; Canzi M; Ceparano G; Serpenti F; De Roberto P; Fabris S; Tagliaferri E; Cavallaro F; Onida F; Fracchiolla NS Front Oncol; 2023; 13():1149298. PubMed ID: 37051529 [TBL] [Abstract][Full Text] [Related]
12. Venetoclax for the treatment of patients with chronic lymphocytic leukemia. Crombie J; Davids MS Future Oncol; 2017 Jun; 13(14):1223-1232. PubMed ID: 28492339 [TBL] [Abstract][Full Text] [Related]
13. Venetoclax for the treatment of chronic lymphocytic leukemia. Gentile M; Petrungaro A; Uccello G; Vigna E; Recchia AG; Caruso N; Bossio S; De Stefano L; Palummo A; Storino F; Martino M; Morabito F Expert Opin Investig Drugs; 2017 Nov; 26(11):1307-1316. PubMed ID: 28972395 [TBL] [Abstract][Full Text] [Related]
14. An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia. Othman TA; Tenold ME; Moskoff BN; Azenkot T; Jonas BA Expert Rev Hematol; 2021 May; 14(5):407-417. PubMed ID: 34076549 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of venetoclax and rituximab in the treatment of concurrent acute myeloid leukemia and untreated chronic lymphocytic leukemia: A case report and literature review. Chen Y; Yuan L; Lu X; Wang X; Zhang Q; Wang X; Zhao X Oncol Lett; 2024 Aug; 28(2):393. PubMed ID: 38966581 [TBL] [Abstract][Full Text] [Related]
16. Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemia. Pelcovits A; Moore J; Bakow B; Niroula R; Egan P; Reagan JL Support Care Cancer; 2021 Sep; 29(9):5323-5327. PubMed ID: 33661367 [TBL] [Abstract][Full Text] [Related]
17. Real-world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience. Laurenti L; Scarfò L; Frustaci AM; Sanna A; Iannella E; Caira M; Finsinger P; Schifano S; Neri B; Molica S; Mauro FR Hematol Oncol; 2023 Oct; 41(4):621-630. PubMed ID: 36680368 [TBL] [Abstract][Full Text] [Related]
18. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Cramer P; von Tresckow J; Bahlo J; Robrecht S; Langerbeins P; Al-Sawaf O; Engelke A; Fink AM; Fischer K; Tausch E; Seiler T; Fischer von Weikersthal L; Hebart H; Kreuzer KA; Böttcher S; Ritgen M; Kneba M; Wendtner CM; Stilgenbauer S; Eichhorst B; Hallek M Lancet Oncol; 2018 Sep; 19(9):1215-1228. PubMed ID: 30115596 [TBL] [Abstract][Full Text] [Related]
19. A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia. Gemici A; Ozkalemkas F; Dogu MH; Tekinalp A; Alacacioglu I; Guney T; Ince I; Geduk A; Cagliyan GA; Maral S; Serin I; Gunduz E; Karakus V; Bekoz HS; Eren R; Pinar IE; Gunes AK; Sargın FD; Sevindik OG Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e686-e692. PubMed ID: 34059487 [TBL] [Abstract][Full Text] [Related]
20. Venetoclax Combination Treatment of Acute Myeloid Leukemia in Adolescents and Young Adult Patients. Chatzikalil E; Roka K; Diamantopoulos PT; Rigatou E; Avgerinou G; Kattamis A; Solomou EE J Clin Med; 2024 Apr; 13(7):. PubMed ID: 38610812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]